Abstract: The present invention relates to improved and integrated methods for the characterisation of an interaction site on a target protein that modulates the phenotype of a mammalian cell, such as a phenotype other than death and/or reduced growth. Such methods of the present invention include those to identify a target protein modulates such a phenotype of a mammalian cell, and optionally to characterise an interaction site on said target protein. Such identification and characterisation methods are useful in the development of research tools and/or therapeutics, such protein/peptide or small molecule therapeutics. Accordingly, the present invention also relates to methods of: identification of a ligand, such as a small molecule ligand, that binds to such a target protein; and identification a compound being a candidate modulator of said phenotype of a mammalian cell.

Abstract: The present invention relates to improved and integrated methods for the characterisation of an interaction site on a target protein that modulates the phenotype of a mammalian cell, such as a phenotype other than death and/or reduced growth. Such methods of the present invention include those to identify a target protein modulates such a phenotype of a mammalian cell, and optionally to characterise an interaction site on said target protein. Such identification and characterisation methods are useful in the development of research tools and/or therapeutics, such protein/peptide or small molecule therapeutics. Accordingly, the present invention also relates to methods of: identification of a ligand, such as a small molecule ligand, that binds to such a target protein; and identification a compound being a candidate modulator of said phenotype of a mammalian cell.

Abstract: An RNAi agent targets a component of a human Notch signalling pathway other than presenilin1 or presenilin2 by RNA interference to reduce expression of said component.

Abstract: A method is provided for reducing an immune response to an allergen or antigenic determinant thereof in a mammal by administering a modulator of the Notch signalling pathway.

Abstract: Provided is a method for modifying IL-4 expression in a cell using a modulator of Notch signalling. Also provided are methods for generating immune modulatory cytokine profiles with increased IL-4 expression and/or increased IL-10 expression and/or reduced IL-5, IL-13 and TNF? expression. In addition, a method for increasing a TH2 immune response and/or decreasing a TH1 immune response in a cell, using a modulator of Notch signalling, is provided. Methods of treatment are also disclosed.

Abstract: Conjugates comprising a plurality of modulators of the Notch signalling pathway chemically bound to a support structure are described. The conjugates are useful for modulation of the Notch signalling pathway and treatment of associated conditions.

Abstract: Provided is a Notch ligand protein or polypeptide comprising a Notch ligand DSL domain; 1 to 5 (but no more than 5) Notch ligand EGF repeat domains; optionally, all or part of a Notch ligand N-terminal domain; and optionally, one or more heterologous amino acid sequences. Also provided is a homogeneous or heterogeneous multimer of the protein or polypeptide and a polynucleotide encoding the Notch ligand protein or polypeptide. An immune response can be modified in a subject by administering the Notch ligand protein or polypeptide to the subject.

Abstract: A method is disclosed for therapeutic modulation of Notch signalling by administering a construct comprising a multiplicity of bond, linked or immobilised modulators of Notch signalling.

Abstract: An inhibitor of the Notch signalling pathway is provided for use as an immunostimulant, for example as a vaccine adjuvant.

Abstract: A method for detecting modulators of Notch signalling is described. The method includes the step of monitoring Notch signalling in a cell of the immune system in the presence of a candidate modulator.

Abstract: An inhibitor of the Notch signalling pathway is provided for the manufacture of a medicament for use in the treatment of cancer.